Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710607 | 0.85 | NR1H2 (0.35) | AGTR2SMN1; SMN2ALDH1A1BCHEMEN1 | |
| SCHEMBL1710530 | 0.83 | AGTR2 (0.37) | AGTR2SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1710688 | 0.82 | AGTR2 (0.37) | AGTR2HSD11B1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL13400165 | 0.81 | AGTR2 (0.35) | AGTR2SMN1; SMN2ALDH1A1BCHEMEN1 | |
| SCHEMBL1710495 | 0.80 | ALDH1A1 (0.38) | AGTR2POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13400238 | 0.77 | HDAC6 (0.38) | SMN1; SMN2ALDH1A1LMNAGAAMEN1 | |
| SCHEMBL1710888 | 0.77 | AGTR2 (0.36) | AGTR2RAB9AKDM4EBCHEKMT2A | |
| SCHEMBL1710552 | 0.77 | POLB (0.36) | AGTR2HSD11B1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL3386705 | 0.76 | ALDH1A1 (0.34) | AGTR2HSD11B1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL13400290 | 0.76 | HDAC6 (0.36) | AGTR2SMN1; SMN2ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | AGTR2 3702/4885HSD11B1 1087/4885POLB 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.